For Immediate Release
Chicago, IL – July 30, 2021 – Zacks Equity Research Shares of Advanced Micro Devices, Inc. (
AMD Quick Quote AMD - Free Report) as the Bull of the Day, NeoGenomics, Inc. ( NEO Quick Quote NEO - Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Microsoft Corporation ( MSFT Quick Quote MSFT - Free Report) , Alphabet Inc. ( GOOGL Quick Quote GOOGL - Free Report) and Amazon.com, Inc. ( AMZN Quick Quote AMZN - Free Report) .
Here is a synopsis of all five stocks:
I've been telling everyone I know about one sure-thing trade all year: buying
Advanced Micro Devices between $75 and $80. My conviction was so strong on this idea because I was closely watching everything competitor NVIDIA was doing and it seemed to me that AMD was doing a lot of the same things just as well, and yet the shares were trading at a significant discount to its bigger peer. I became convinced about buying AMD pullbacks a year ago in July after the stock broke-out strongly from a consolidation around $55. The catalyst was another advance in the PC wars against rival Intel. I covered that in this article and video... Release the Ryzen! AMD Roars in the Nanometer Wars I also expanded my knowledge of how the little gaming chip company had undergone an "advanced" semiconductor revolution in the past six years under the leadership of Taiwan-born engineer Lisa Su. Early in her career, Su worked at Texas Instruments, IBM, and Freescale Semiconductor in engineering and management positions. As an industry outsider -- and semiconductors is a complex industry involving microscopic physics -- I was focused on how NVIDIA and fellow Taiwan engineer Jen-Hsun "Jensen" Huang had turned the gaming GPU chip (graphics processing unit) into the foundations of machine learning and artificial intelligence (AI). So when I learned that Lisa Su was basically doing the same things, but with her own brands of excellence, I was hooked to learn more. And coming up, I'll show you good comparisons of these two Taiwanese chip ninjas and what their teams of excellent engineers are able to create with the "massively parallel architectures" of GPUs. AMD Surges From $80 to $105 Since June 17
I hope you were listening in March when I explained how I got my son and his wife to buy AMD at $75 with a resting limit order. I covered that in
Flush Draw: How to Beat the Algos When They Run the Stops. You even got a bunch more chances to buy AMD shares near $73 in the middle of May. I think part of the pessimism was over the company's planned $35 billion acquisition of Xilinx and whether or not regulators would approve it. The all-stock deal for the FPGA chip maker was announced in late October and on April 7, both boards approved the deal, describing the marriage thus in the press release... The acquisition will bring together two industry leaders with complementary product portfolios and customers, combining CPUs, GPUs, FPGAs, Adaptive SoCs and deep software expertise to enable leadership in computing platforms for cloud, edge and end devices. Together, the combined company will have the ability to capitalize on opportunities spanning some of the industry's most important growth segments, including data centers, gaming, PCs, communications, automotive, industrial, aerospace and defense. Well, the mood started to improve in the middle of June, even before UK and European regulators gave the deal their thumbs up. It began with a 5.5% pop in AMD shares on June 17 after the Lisa Su juggernaut announced that Alphabet unit Google Cloud had selected AMD EPYC processors to power its new datacenters. And despite deteriorating economic and market relations with China -- which could lead one to believe that the last regulator to approve the AMD-XLNX deal might get stingy -- shares of AMD have marched to all-time highs above $100 this week. Lisa & Co. Deliver the Goods
The catalyst for this week's double-digit rally from $92 was another stellar beat-and-raise quarter. AMD reported second-quarter 2021 non-GAAP earnings of 63 cents per share, which surpassed the Zacks Consensus Estimate by 16.7%. The bottom line soared 250% year-over-year and 21% sequentially.
Revenues of $3.85 billion outpaced the Zacks Consensus Estimate by 6.4% and surged 99% y-o-y. On a sequential basis, the top line increased 12%. Robust performance from the Computing and Graphics, and Enterprise Embedded and Semi-Custom segments drove the improvements. "Our business performed exceptionally well in the second quarter as revenue and operating margin doubled and profitability more than tripled year-over-year," said AMD president and CEO Lisa Su. "We are growing significantly faster than the market with strong demand across all of our businesses. We now expect our 2021 annual revenue to grow by approximately 60 percent year-over-year driven by strong execution and increased customer preference for our leadership products." That full-year revenue projection comes after the prior forecast of +50%. Top-Line Growth Details
Computing and Graphics segment revenues of $2.25 billion increased 65% y-o-y and 7% sequentially. The upside can be attributed to higher revenues from client processor and graphics sales.
Growth in client processor average selling price (ASP) was driven by a favorable mix of Ryzen desktop and notebook processor sales. GPU ASP growth in the reported quarter was driven by strong high-end graphics product sales, including data center GPU sales. AMD's Ryzen Embedded Processors and RDNA 2-based GPUs are now being used by Tesla to power the infotainment system in its new Model S and X vehicles. Valve announced Steam Deck powered by a semi-custom AMD processor. AMD also introduced FidelityFX Super Resolution ("FSR"), its latest spatial upscaling algorithm feature, which boosts frame rates and delivers high-quality, high-resolution gaming experiences. More than 40 game developers have already pledged support for FSR. Enterprise, Embedded and Semi-Custom segment revenues of $1.60 billion were up 183% y-o-y and 19% sequentially. The increase is attributed to higher semi-custom product sales and EPYC processor revenues. EPYC's adoption rate continued to increase in the quarter. AMD and its partners, including Microsoft and Alphabet, announced several new high-performance computing systems. These include Microsoft Azure supercomputers for the United Kingdom's Met Office, The Perlmutter supercomputer and The Singapore National Supercomputing Centre build. How Much More Upside from $105?
In a moment, I'm going to share some Wall Street analyst reactions and their price target bumps for AMD. But I'll tell you right now that quite a few are sticky around $110. Some outliers see $125 and one is even targeting $150.
So can you still invest in AMD here even if you missed the good buys near $80? I think so and not only am I not selling any of my shares, I'll be looking to add on dips. For more insight into why I think this way, check out these two recent articles and videos I produced... AI Dreams and Reality: Investing in Advanced Technology NVIDIA and AMD: Digital Flywheels of Super-Exponential Innovation Analysts Chime In
Here were select comments and price target (PT) moves by Wall Street semiconductor analysts...
Jefferies: Analyst Mark Lipacis kept AMD as one of his top picks and reiterated his $110 PT. Lipacis has over 2 decades experience in analysis of the semiconductor industry and he convinced me last year how quickly NVIDIA was going to ramp its datacenter business to be bigger than gaming, especially if the proposed ARM Holdings acquisition goes through. Now he sees AMD server share gains accelerating to be greater than 25% of their business this year. Lipacis estimates AMD server CPU revenues increased by 33% quarter-over-quarter, compared to 16% for Intel. Mizuho: Analyst Vijay Rakesh raised the firm's PT on AMD to $110 from $107 and reiterated a Buy rating on the shares after the "strong" June quarter results. However, the analyst believes investors may be starting to get concerned over the 2022 and 2023 PC outlook. So here's a bull who was right all year heading into this quarter, but now is getting cautious and would probably be advising his clients to take some profits as the stock busts through $105 as I type on Thursday afternoon. Susquehanna: Analyst Christopher Rolland raised his PT on AMD to $130 from $125 and kept a Positive rating on the shares. The analyst said he anticipated upside results and guidance but he had not expected the company to navigate supply constraints flawlessly and raise full year expectations. Another AMD bull who stays very bullish. Raymond James: The analysts reiterated their Outperform rating and $110 PT, citing the unexpected boost in guidance being driven mainly by the server business. Their analysis, based on Intel and AMD guidance, suggests that AMD is poised to take about 2% server share in each of 3Q and 4Q, in contrast to Intel's expectations to hold server share in 2H21. "And that's before AMD launches the more powerful Genoa server platform, for which we expect significant incremental performance gains since that product will move to the TSMC N5 node." That bit of industry code at the end refers to Taiwan Semiconductor and 5-nanometer technology. The RJ analysts sum up the competitive edge of AMD vs INTC: "Since Intel's recent roadmap indicates that AMD will be working with a transistor advantage at least through 2024, we think AMD simply needs to continue doing what they're doing and the market share will come their way." They raised their 2022 EPS estimates to $3.08 while the Zacks Consensus stood at $2.70 before the report. Northland: Analyst Gus Richard raised his PT to $125 per share, noting "All product lines are driving growth and AMD is winning higher margin SKUs. We believe AMD outperformance is drive by superior products built on a superior manufacturing process. We do not expect this advantage to diminish any time soon." Rosenblatt: Analyst Hans Mosesmann hiked his PT to $150 per share from $135 following "another big beat-and-raise" quarter. "This time is even more compelling given industry supply chain shortages and an increasingly more vulnerable Intel (weaker portfolio and delays of next generation CPUs). AMD took up sales growth for 2021 to the 60% level from 50% (and 37% from January) on broad-based demand and share gains on everything they offer, literally. All new 5nm roadmap confirmed on-track for 2022." Now let's check in with a recalcitrant bear... BMO Capital: Analyst Ambrish Srivastava raised the firm's PT on AMD to $80 from $75 but kept an Underperform rating on the shares. Despite strong Q2 results and guidance, with growth in the server "side business" remaining robust, the analyst believes AMD still faces a "re-energized" Intel and its market share gains will likely moderate. As I've been saying all year, what bears don't get is that AMD is the #2 supplier behind NVIDIA in hyperscale datacenter... and #1 if you ask Google. Plus it trades at less than half NVDA's 17X sales valuation. Buy the dips in AMD. And you'll get some (I hope), just like we did from $95 last winter down to $75. Maybe the next market pullback will give you another shot at $95. Maybe. NeoGenomics is a $5.3 billion provider of clinical laboratory services that specializes in cancer genetics and diagnostic testing, the fastest growing segment of the laboratory industry.
The company's high-complexity CLIA-certified testing services include cytogenetics, flow cytometry, morphology studies, anatomic pathology, molecular genetic testing, and fluorescence in-situ hybridization, a molecular cytogenetic technique that uses fluorescent probes that bind to only those parts of a nucleic acid sequence with a high degree of sequence complementarity.
Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.
Why the Zacks #5 Rank?
NEO had a big reset in its path to consistent profitability this year. Just over two months ago, the analyst EPS consensus was looking for a 20% annual advance to 18-cents per share.
But since the company's last quarterly update in early May, that outlook has been slashed to
minus 21-cents EPS, for a -240% annual decline.
Part of the profit decline may be due to a recent flurry of acquisitions the company has made in the testing space, that are diluting both its cash and shares.
In March NeoGenomics made a deal to acquire Trapelo Health, an information technology company focused on precision oncology, for $65 million in cash and stock. At the time, analysts from Needham & Co. wrote...
"We believe that the Trapelo Health acquisition complements NeoGenomics' growing informatics offering, combining precision medicine with NeoGenomics' leading test menu, expanding patient database, and access to healthcare networks, cancer centers, and laboratories."
Then in May NeoGenomics exercised an option to acquire the remaining equity interest in the UK-based Inivata, Ltd. for $390 million. NEO acquired a minority stake in Inivata, a commercial-stage liquid biopsy platform company, in May 2020 for $25 million, with a fixed-price option to purchase the remaining equity.
The acquisition will help expand the market opportunity for NeoGenomics, as well as accelerate its long-term growth rate with increasing adoption of liquid biopsy for therapy selection in the community setting. The company said at the time it would fund the deal using its available cash and proceeds from a concurrent private placement of $200 million of equity to a group of institutional investors.
Why NEO Should Stay On Your Oncology Radar
I invest heavily in this space and I'm just learning about NEO. At any given time I either own shares or am trading shares of
Exact Sciences, Guardant Health, Invitae and Natera for my Healthcare Innovators portfolio.
That's because I believe the most important revolution in medicine right now is the one involving what I call "The 5 P's of Powerful Healthcare"...
Proactive Precise Predictive Preventive
And that's what all these companies do in different ways to gain early detection of cancer, monitor vital biochemistry and organ systems, or diagnose potential genetic, hereditary and lifestyle issues that may predispose a patient to a certain disease.
In the new era of "tele-health," it's more important than ever for doctors and patients to work together on The 5 P's. To learn more about them, and all these fantastic companies, stop by my
Healthcare Innovators portfolio soon.
From Natera giving families early knowledge about their babies with non-invasive prenatal screening to Exact Sciences giving early detection of colon cancer with home test kits, the field of diagnostics is exploding with innovation and competition that will raise awareness and slash costs.
And right now, NEO has one of the best valuation pictures among all these companies, trading at under 10 times forward sales projections. So when the EPS estimates stop going down for NEO, it may be time to invest. The Zacks Rank will let you know.
Additional content: 3 Stocks to Watch as Adoption of MLaaS Continue to Grow
The importance of machine learning ("ML") has been increasing over the years as organizations are making use of this technology to automate processes among other usages. ML can train artificial intelligence ("AI") to perform a task without necessarily requiring human assistance. But setting up an ML infrastructure can be cost-intensive, making it difficult for certain firms to afford. This is where machine learning as a service (MLaaS) has come to the forefront.
With the help of MLaaS, organizations can have access to pre-programmed ML tools to utilize for their operations and customize according to their needs. This can significantly reduce the cost of developing and maintaining ML projects as firms don't have to incur such expenses at their end. This is because MLaaS offerings are available on cloud platforms which also means that firms can easily access such tools, simply with an Internet connection.
Cloud adoption has been growing over the years owing to the conveniences it provides to organizations including easy access, flexibility, affordability, and so on. The outbreak of the coronavirus pandemic last year only accelerated cloud adoption as remote working led companies to rapidly shift to the cloud model. Even as we move beyond the pandemic, cloud computing looks ready to stay as its benefits outweigh the traditional ways of developing projects, and MLaaS, as part of cloud computing, should also witness growth.
Since MLaaS offers developers a pre-built set of tools and services, it reduces the time that would be spent in developing such tools before implementing them in a project. In fact, a
Neuromation article stated that certain MLaaS providers also give users access to pre-made application programming interfaces for predictive analytics, image recognition, sentiment analysis, and other ML use cases.
The initial setup and maintenance is taken care of by MLaaS providers. So, organizations can focus more on developing their projects, thereby reducing the completion time. This can lead them to launch their products or services at a faster pace and be more competitive.
Reflective of the benefits that MLaaS is providing to firms, the MLaaS market seems poised to grow. Per a
report by Mordor Intelligence, the MLaaS market should witness a CAGR of 39.86% from 2021 to 2026. The report further stated that factors like the Internet of Things, automation, demand for consumer behavior analytics, among others, are expected to drive the growth of MLaaS. 3 Stocks to Watch
The adoption of MLaaS seems ready to grow in the near term as it offers organizations benefits like reduced cost, pre-built tools for developing projects, reduced completion time, and so on. To take advantage of the potential of MLaaS, it will be prudent to take a look at companies that stand to benefit from it.
We have selected three such stocks that carry a Zacks Rank #2 (Buy) or 3 (Hold). You can see
the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Microsoft seems to be benefiting from the rapid adoption of cloud computing and ML. The company offers MLaaS through its Azure ML cloud platform, allowing data scientists and developers to build, train and deploy ML models and boost productivity.
Shares of Microsoft have gained 28.7% year to date and it currently has a Zacks Rank #2. The Zacks Consensus Estimate for its current-year earnings increased 0.2% over the past 60 days. The company's expected earnings growth rate for the current year is 4.3%.
Alphabet’s Google offers AutoML via its Google Cloud platform. On May 18, Google announced the general availability of Vertex AI, which unifies Google Cloud's existing ML offerings into a single environment that will allow companies to build, train and deploy ML models.
Shares of Alphabet have risen 55.3% year to date and it currently carries a Zacks Rank #3. The Zacks Consensus Estimate for its current-year earnings increased nearly 1% over the past 60 days. The company's expected earnings growth rate for the current year is 53.8%.
Amazon.com offers MLaaS services through its Amazon Web Services ("AWS") platform. Amazon recently launched Amazon Lookout for Metrics, which uses ML to automatically detect anomalies in metrics and diagnose them. On Jun 23, AWS announced the expansion of its partnership with Salesforce, allowing customers to innovate faster with pre-built applications combining AWS and Salesforce Customer 360. Salesforce will also embed AWS services for ML, AI, and others, directly in new applications for sales and other use cases.
Shares of Amazon have gained 11.5% year to date and the company currently has a Zacks Rank #3. The Zacks Consensus Estimate for its current-year earnings increased 1.6% over the past 60 days. The company's expected earnings growth rate for the current year is 36.7%.
Zacks Investment Research
800-767-3771 ext. 9339
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit
https://www.zacks.com/performance for information about the performance numbers displayed in this press release.